• 1
    Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 37: 20102018.
  • 2
    AGA Clinical Practice Committee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941966.
  • 3
    Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50(suppl 1): 19.
  • 4
    Guichelaar MMJ, Malinchoc M, Sibongo J, Clarke BL, Hay JE. Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl 2004; 10: 638647.
  • 5
    Crawford BA, Labio ED, Strasser SI, McGaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 689699.
  • 6
    Peris P, Guanabens N, Pares S, Pons F, del Rio L, Monegal A, et al. Vertebral fracture and osteopaenia in chronic alcoholic patients. Calcif Tissue Int 1995; 57: 111114.
  • 7
    Mobarhan SA, Russell RM, Recker RR, Posner DB, Iber FL, Miller P. Metabolic bone disease in alcoholic cirrhosis: a comparison of the effects of vitamin D2, 25 hydroxyvitamin D or supportive treatment. HEPATOLOGY 1984; 4: 266273.
  • 8
    Kaymakoglu S, Okten A, Cakalogu Y, Boztas G, Besisik F, Tascioglu C, et al. Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol 1995; 30: 745750.
  • 9
    Pares A, Guanabenes N, Rhodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 331335.
  • 10
    Boyle WJ, Scott-Simonet W, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337342.
  • 11
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhlleschner P, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005; 43: 973983.
  • 12
    Gallejo-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moneno D. Bone mineral density, serum insulin like growth factor I and bone turnover markers in viral cirrhosis. HEPATOLOGY 1998; 28: 695699.
  • 13
    Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, et al. Osteopaenia in rats with liver cirrhosis: beneficial effects of IGF-1 treatment. J Hepatol 1998; 28: 122131.
  • 14
    Smith DL, Shire NJ, Watts NB, Schmitter T, Szabo G, Zucker SD. Hyperbilirubinaemia is not a major contributing risk factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom 2006; 9: 105113.
  • 15
    Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and the prevention of fractures. Arch Intern Med 2006; 166: 12561261.
  • 16
    Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1980; 31: 8287.
  • 17
    Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of the cirrhosis? J Gastroenterol Hepatol 1996; 11: 417421.
  • 18
    Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148154.
  • 19
    Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, et al. Bone disease in patients with sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998; 29: 729735.
  • 20
    Ninkovic M, Skingle SJ, Bearcroft PWP, Bishop N, Alexander GJM, Compston JE. Incidence of vertebral fracture in the first three months following orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000; 12: 931935.
  • 21
    Carey EJ, Balan V, Kremers WK, Hay JE. Osteopaenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003; 9: 11661173.
  • 22
    Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004; 10: 648653.
  • 23
    Guichelaar M, Schmoll J, Malinchoc M, Hay EJ. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. HEPATOLOGY 2007; 46. doi: 10.1002/hep.21805.
  • 24
    Guichelaar MMJ, Kendall R, Schmoll J, Malinchoc M, Hay JE. Bone mineral density before and after OLT; long-term follow-up and predictive factors. Liver Transpl 2006; 12: 13901402.
  • 25
    Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? HEPATOLOGY 1995; 21: 389392.
  • 26
    Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42: 573577.
  • 27
    Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 2006; 131: 17521757.
  • 28
    Sinigaglia L, Fargion S, Francanzani AL, Binelli L, Battafarano N, Verema M, et al. Bone and joint involvement in genetic haemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997; 24: 18091813.
  • 29
    Guggenbuhl P, Deugnier Y, Boisdet JF, Rollnad Y, Perdriger A, Pawlotsky Y, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutations. Osteoporos Int 2005; 16: 18091814.
  • 30
    Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 812817.
  • 31
    Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, et al. World J Gastroenterol 2005; 11: 18431847.
  • 32
    Floerani A, Mega A, Tizian L, Boccagni P, Baldo V, Fagiuoli S, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 2001; 12: 749754.
  • 33
    Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol 2006; 45: 445453.
  • 34
    Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol 1999; 34: 241245.
  • 35
    Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 22682274.
    Direct Link:
  • 36
    Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled study. HEPATOLOGY 2005; 42: 762771.
  • 37
    Monegal A, Navasa M, Suaraz M, Suaraz-Lopez S, Garcia-Gonzalez F, Serrano T, et al. Effects of intravenous pamidronate on bone loss after liver transplantation [Abstract]. Calcif Tissue Int 2006; 78: S148.
  • 38
    Crawford BA, Kam C, Pavlovic J, Blyth K, Handlelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized double blind, placebo-controlled trial. Ann Intern Med 2006; 144: 239248.
  • 39
    Woo S-B, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99102.
  • 40
    Pereira SP, O'Donohue J, Moniz C, Phillips MG, Abraha H, Buxton-Thomas M, et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1 year controlled trial. Aliment Pharmacol Ther 2004; 19: 563570.
  • 41
    Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomised trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006; 51: 11031112.
  • 42
    Ormarsdottir S, Mallmin H, Naessen T, Petren-Mallmin M, Broome U, Hultcrantz R, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004; 256: 6369.
  • 43
    Levy C, Harnois DM, Angulo P, Jargensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005; 25: 117121.
  • 44
    Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. HEPATOLOGY 1991; 21: 389392.
  • 45
    Meys E, Fontanges E, Fourcade N, Thomasson A, Poyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994; 97: 445450.
  • 46
    Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonate treatment in bone loss after liver transplantation. Calcif Tissue Int 1997; 60: 148154.
  • 47
    Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998; 4: 404409.
  • 48
    Leidig-Bruckner G, Hosch S, Dodidou P, Risteli J, Conradt C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation. Lancet 2001; 357: 342347.